Dr. Angela Goffredo Fleischman, MD

Dr. Fleischman practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Fleischman's NPI, 1922216175, was assigned on May 20, 2007. Dr. Fleischman graduated from Stanford University School Of Medicine in 2005. Dr. Fleischman holds California license A125078.

Dr. Fleischman's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Fleischman's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fleischman practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Fleischman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Fleischman is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Fleischman's licenses on file in 2 states: California and Oregon.

Dmand AI lists sepsis among the conditions Dr. Fleischman treats.

CMS data shows 256 Medicare services from Dr. Fleischman across 3 procedure codes in 2024, for 100 Medicare patients. Medicare paid $20,712 for them.

CMS counts 100 Medicare patients who saw Dr. Fleischman in 2024. The largest group is 65 to 74, with 44 patients. 72% of them have high cholesterol, and 71% have high blood pressure. 19% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fleischman's median patient age at 65, with 54% women.

In 2024, Dr. Fleischman wrote 285 Medicare Part D claims for 46 patients. CMS names the drug for 234 of them, across 6 drugs with 11 or more claims each, at $2,620,422 in total drug cost. In 2023, CMS named 187 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Fleischman for performance year 2024, reported through an alternative payment model (APM). Dr. Fleischman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fleischman as offering telehealth.

Dmand AI links 57 papers to Dr. Fleischman, published from 2011 to 2025. 2023 was the busiest year, with 11. The most frequent topics are Myeloproliferative Disorders, Protein Kinase Inhibitors and Janus Kinase 2. Dr. Fleischman has published most often in Blood. Dr. Fleischman's most frequent co-authors are Brian Jay Druker, MD, Ruben Anthony Mesa, MD and Jason Gotlib, MD, MS.

Dmand AI links Dr. Fleischman to 5 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Myeloproliferative Disorders, Thrombocythemia, Essential and Thrombocytosis. University of California, Irvine sponsors the most, 3.

CMS Open Payments shows 211 general payments to Dr. Fleischman from 11 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Incyte Corporation paid the most, $74,874. It also lists 1 research payment totaling $1,820 in 2022.

Dr. Fleischman graduated from Stanford University School Of Medicine in 2005.

Dr. Fleischman is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.